CatalYm has reported final Phase 2 GDFATHER-NEO findings showing that its investigational anti-GDF-15 antibody visugromab increased pathologic complete response rates when combined with nivolumab in patients with newly diagnosed muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. Presented at the European Society for Medical Oncology Congress 2026 on October 24 and simultaneously published in Nature Medicine, the results showed pathologic complete responses in 33% of patients receiving visugromab plus nivolumab, compared with 8% receiving nivolumab and placebo.
The study also reported higher major pathologic response and radiographic objective response rates with the combination, providing additional evidence supporting growth differentiation factor 15 inhibition as a potential strategy for addressing resistance to immune checkpoint therapy. CatalYm is developing visugromab to neutralise GDF-15, a protein associated with immune suppression within tumors and several other biological effects relevant to cancer.
The findings are scientifically relevant because they suggest that changing the tumor’s immunosuppressive environment could increase the activity of PD-1 blockade before definitive local treatment. However, GDFATHER-NEO enrolled only 31 participants and was designed as an exploratory Phase 2 investigation without formal confirmatory hypothesis testing. The response differences therefore support further clinical development but do not establish a survival advantage or justify routine omission of radical cystectomy.
What do the final GDFATHER-NEO results show about pathologic complete response in bladder cancer?
GDFATHER-NEO was a multicentre, stratified, single-blind Phase 2 trial evaluating visugromab combined with nivolumab against nivolumab plus placebo. The study enrolled patients with newly diagnosed, non-metastatic muscle-invasive bladder cancer who were unsuitable for cisplatin-based chemotherapy or declined that treatment. Participants had not previously received immune checkpoint inhibitors, making the study relevant to evaluating GDF-15 blockade in an immunotherapy-naive population.
A total of 31 participants entered the trial, with 16 assigned to visugromab plus nivolumab and 15 to the control regimen. The median age was 76 years, reflecting an older population in which treatment suitability and surgical considerations can be particularly important. For the final locally assessed efficacy analysis, 15 participants in the combination group and 13 in the control group were evaluable.
Five of the 15 evaluable patients receiving visugromab and nivolumab achieved a pathologic complete response, corresponding to 33.3%. In the nivolumab and placebo group, one of 13 patients achieved the same outcome, representing 7.7%. The observed difference of approximately 25.6 percentage points favoured the experimental combination.
Pathologic complete response refers to the absence of detectable residual invasive cancer meeting the study’s defined pathological criteria following treatment. In the neoadjuvant setting, this measurement provides an early indication of antitumor activity before or during definitive local treatment. It does not necessarily demonstrate that all microscopic disease has been eliminated throughout the body or establish that recurrence cannot occur.
The study also reported major pathologic responses in nine of 15 patients receiving the combination, compared with three of 13 receiving nivolumab alone. These correspond to rates of 60% and approximately 23%, respectively. Major pathologic response includes patients whose disease has regressed to the defined lower pathological stage, providing a broader assessment of treatment activity than complete response alone.
The magnitude of these numerical differences is encouraging, particularly because the control group received an active immune checkpoint inhibitor rather than no systemic treatment. Nevertheless, the small number of participants creates substantial uncertainty around the response estimates, and the results should not be interpreted as definitive evidence of superior clinical efficacy.
How do the radiographic response results support the findings from pathological assessment?
In addition to pathological endpoints, GDFATHER-NEO evaluated changes in measurable disease using radiographic assessment. The locally assessed objective response rate was 60% in the visugromab combination group, compared with approximately 15% in the nivolumab and placebo group. Nine of 15 evaluable patients receiving the combination achieved an objective response, compared with two of 13 in the control group.
The experimental arm included seven patients classified as having complete radiographic responses under local assessment. This finding suggests substantial tumor regression in several participants receiving visugromab alongside nivolumab. However, radiographic complete response should not be considered equivalent to pathologic complete response because imaging and tissue examination assess different aspects of treatment activity.
Independent blinded central review provided additional context. For pathological complete response, central reviewers identified seven responses among 15 evaluable combination-treated patients, compared with two among 12 evaluable control patients. This corresponded to rates of approximately 47% and 17%, respectively, preserving the direction of the difference observed locally.
The independent radiographic findings were less widely separated than the local results. Central review identified objective responses in eight of 16 combination-treated patients and four of 12 control patients, corresponding to rates of 50% and 33%. These differences show why central assessment should be considered independently rather than merely described as confirmation of every locally reported response estimate.
Variation between local and central radiographic interpretation can occur because of differences in imaging assessment, tumor measurement and classification of response. In a small study, relatively minor differences in patient classification can materially change the reported percentages. The findings therefore support the overall biological signal while reinforcing the need for larger controlled trials.
The fact that pathological and radiographic measurements generally favoured the combination is relevant, but the study was not powered to establish a definitive treatment advantage. A confirmatory programme would need prespecified endpoints, suitable statistical controls and enough participants to distinguish a reproducible effect from sampling variability.
Why could blocking GDF-15 make PD-1 immunotherapy more effective?
Visugromab is a humanised monoclonal antibody designed to neutralise growth differentiation factor 15, or GDF-15. This protein can be produced by tumors and other tissues and has been implicated in immune suppression, tumor progression and cancer-associated metabolic effects. Its biological activities make it an emerging therapeutic target across several solid tumor settings.
CatalYm’s research has focused on the possibility that GDF-15 can interfere with effective antitumor immune-cell activity. In some tumor environments, increased GDF-15 signalling may contribute to limited immune-cell infiltration or reduced responsiveness to immune checkpoint inhibition. Neutralising the protein is intended to modify these conditions and potentially make checkpoint therapy more effective.
Nivolumab blocks programmed cell death protein 1, or PD-1, an immune checkpoint receptor involved in regulating T-cell activity. By preventing inhibitory signalling through this pathway, the medicine can support immune responses against cancer cells. However, the effectiveness of PD-1 blockade also depends on whether suitable immune cells are present and capable of functioning within the tumor environment.
The combination therefore investigates two related but distinct immunological processes. Nivolumab seeks to release a checkpoint-associated constraint on T-cell activity, while visugromab is intended to address a separate component of tumor-associated immune suppression. The hypothesis is that neutralising GDF-15 may improve the conditions required for PD-1 blockade to generate an antitumor response.
The Phase 2 findings are consistent with that proposed mechanism because adding visugromab was associated with higher response rates. Nevertheless, they do not independently establish which specific cellular interactions caused the additional responses or demonstrate that every patient with elevated GDF-15 activity will benefit.
Mechanistic validation will require further investigation of tumor tissue, immune-cell activity and treatment-associated changes. Such research may help distinguish direct effects of GDF-15 neutralisation from other biological factors contributing to response.
What do the biomarker findings reveal about patients most likely to respond?
CatalYm reported that baseline infiltration by proliferating CD8-positive T cells was associated with response to visugromab plus nivolumab. CD8-positive T cells are important components of the antitumor immune response, and evidence of cellular proliferation may provide information about the functional state of immune activity within a tumor. Their presence could therefore have relevance when investigating combinations intended to enhance T-cell-mediated cancer control.
The observation is consistent with the proposed mechanism of visugromab, which aims to alter immune suppression and improve the conditions under which checkpoint blockade operates. Tumors already containing an active immune-cell population may be more capable of generating a measurable response when additional inhibitory mechanisms are targeted. However, this remains a hypothesis arising from exploratory biomarker research.
The available evidence does not establish a validated treatment-selection test. No clinically authorised threshold has been defined for proliferating CD8-positive T-cell infiltration, and the study was too small to confirm that this measurement reliably predicts differential treatment benefit.
Additional analyses have indicated that baseline GDF-15 measurements and PD-L1 combined positive score did not consistently distinguish responders from nonresponders within the small study population. Such findings illustrate the challenge of translating a biologically relevant pathway into a practical predictive biomarker. The presence of a target protein does not necessarily identify which patients will derive the greatest clinical benefit from blocking it.
Future studies could investigate whether combinations of immune-cell characteristics, GDF-15 measurements and conventional clinical factors improve patient selection. Any biomarker strategy would need independent validation and evidence that using the measurements to guide treatment produces meaningful benefits.
Could visugromab and nivolumab help selected patients avoid radical cystectomy?
One of the most clinically consequential observations concerns the possibility of bladder preservation following neoadjuvant treatment. Radical cystectomy is an established potentially curative treatment for muscle-invasive bladder cancer, but removal of the bladder can have substantial consequences for urinary function, sexual health and quality of life. Treatment strategies capable of preserving the bladder without compromising cancer control are therefore an important research objective.
In GDFATHER-NEO, six of 16 patients assigned to visugromab plus nivolumab underwent repeat transurethral resection of the bladder tumor rather than radical cystectomy after neoadjuvant therapy. This represented 37.5% of the experimental group, compared with three of 15 patients, or 20%, in the control group. The difference suggests greater use of a bladder-preserving local treatment approach among patients receiving the investigational combination.
Among the five combination-treated patients who achieved a locally assessed pathologic complete response, four retained their bladder following repeat transurethral resection alone. This finding provides early clinical evidence relevant to organ-preservation research, particularly in patients who might otherwise face substantial consequences from radical surgery.
However, the observation does not demonstrate that radical cystectomy can safely be omitted in patients responding to the combination. The relevant subgroup involved only four patients retaining their bladder, and follow-up was insufficient to establish long-term local disease control, survival or functional outcomes.
Bladder preservation requires confidence that residual invasive disease and future recurrence can be detected and managed appropriately. A clinical complete response based on imaging and transurethral tissue assessment may not identify every focus of disease, creating a need for rigorous surveillance and appropriate patient selection.
The next development challenge is therefore not merely achieving a higher complete response rate. It is establishing whether response-guided bladder preservation can maintain oncological outcomes comparable to accepted definitive treatment while delivering meaningful quality-of-life advantages.
Does the 15.7-month follow-up establish durable cancer control?
The final analysis used a July 15, 2026 data cutoff and included a median follow-up of 15.7 months. CatalYm reported no recurrences among patients who achieved a pathologic complete response, comprising five patients in the combination arm and one in the control arm. This observation is encouraging within the disclosed follow-up period but remains based on a very small subgroup.
Median event-free survival had not been reached in either treatment group. The available follow-up included approximately one year after surgery, limiting the ability to assess whether the response differences will translate into lower long-term recurrence rates. No comparative event-free survival hazard ratio establishing benefit was reported.
The distinction between pathological response and durable disease control is particularly important in muscle-invasive bladder cancer. Some patients experience recurrence despite favourable early treatment findings, while others may remain free of disease for prolonged periods after surgery. The relationship between an early response and later clinical outcomes therefore requires longitudinal evaluation.
The trial also included different approaches to local treatment following neoadjuvant therapy. Some patients underwent radical cystectomy, while others received repeat transurethral resection. These differences can complicate interpretation of recurrence patterns in a small exploratory population.
The final Phase 2 findings demonstrate higher short-term response rates, not a confirmed reduction in recurrence risk or mortality. Larger studies with longer follow-up will be needed before the treatment can be described as improving event-free or overall survival.
What do the safety results show about adding visugromab to nivolumab before surgery?
CatalYm reported that visugromab plus nivolumab was generally well tolerated and that no new safety signals emerged during the disclosed study. Most treatment-related adverse events were mild or moderate, and no treatment-related discontinuations or treatment-related delays to surgery were reported in the experimental group. These findings support further investigation of the combination in a neoadjuvant setting.
Detailed safety reporting indicated that Grade 3 or 4 treatment-related adverse events occurred in two of 16 patients receiving the combination and three of 15 receiving nivolumab plus placebo. These correspond to approximately 13% and 20%, respectively. The numerical comparison is encouraging but too small to establish a definitive safety advantage.
Nivolumab has an established safety profile that includes immune-mediated adverse reactions involving the lungs, liver, gastrointestinal tract, endocrine organs and other systems. Adding another immune-modulating antibody requires careful evaluation of whether the combination changes the frequency, severity or duration of these complications. A small Phase 2 trial cannot exclude uncommon but clinically important toxicities.
The surgical context creates additional safety requirements. Neoadjuvant treatment must be delivered without causing complications that prevent or substantially delay definitive local treatment. The absence of reported treatment-related surgical delays in the visugromab group is therefore relevant, although it does not guarantee similar outcomes in larger or less selected populations.
Future trials will need to evaluate treatment discontinuation, immune-related events, postoperative complications and longer-term consequences. The balance between increased response and any additional treatment burden will be central to determining whether GDF-15 inhibition offers a practical advantage in potentially curative bladder cancer treatment.
How does GDFATHER-NEO fit into the changing muscle-invasive bladder cancer treatment landscape?
The treatment environment for muscle-invasive bladder cancer has advanced considerably, particularly for patients unable to receive cisplatin-based chemotherapy. In November 2025, the United States Food and Drug Administration approved pembrolizumab with enfortumab vedotin as neoadjuvant treatment followed by postoperative therapy for adults with muscle-invasive bladder cancer who were ineligible for cisplatin. That approval was supported by randomised Phase 3 evidence demonstrating improvements in event-free and overall survival.
The indication was subsequently expanded in July 2026 to include adults with muscle-invasive bladder cancer who were candidates for cystectomy, regardless of cisplatin eligibility. This development established a broader treatment option combining immune checkpoint blockade with an antibody-drug conjugate. Its availability changes the clinical benchmark that future neoadjuvant therapies must address.
AstraZeneca has also reported positive Phase 3 VOLGA results involving durvalumab and enfortumab vedotin in cisplatin-ineligible or cisplatin-refusing patients. Those findings demonstrated improvements in event-free and overall survival against a surgery-based comparator. The investigational VOLGA regimen represents a separate treatment strategy from CatalYm’s GDF-15-directed combination.
GDFATHER-NEO differs from these programmes in both development stage and therapeutic approach. It investigates whether adding GDF-15 neutralisation to PD-1 blockade can increase response before local treatment, rather than combining checkpoint inhibition with an antibody-drug conjugate. The scientific distinction may eventually support alternative combination strategies, but no direct comparative evidence establishes their relative efficacy.
CatalYm’s programme also remains substantially earlier in development. Its Phase 2 response results cannot be compared directly with mature Phase 3 survival findings to determine which regimen is more effective. The clinical standards for a future visugromab programme will need to reflect the increasing availability of approved perioperative treatments.
A meaningful commercial position may ultimately depend on demonstrating benefits in a specific patient population, a favourable safety profile or a validated bladder-preservation strategy. The current study identifies possible development directions without establishing which will provide the strongest clinical value.
Why is CatalYm expanding visugromab into lung cancer, liver cancer and cachexia?
CatalYm is developing visugromab as a broader therapeutic platform centred on GDF-15 neutralisation rather than a medicine limited to bladder cancer. The company is evaluating the antibody across several solid tumor indications and treatment settings, reflecting its hypothesis that GDF-15 contributes to immune suppression in multiple malignancies. Its broader programme also investigates the protein’s role in cancer-associated cachexia.
The company has initiated randomised Phase 2b studies of visugromab-based combinations in first- and second-line non-squamous non-small cell lung cancer. It is also investigating the medicine in second-line hepatocellular carcinoma, where the ability to improve responses after previous systemic treatment could be clinically relevant. These programmes remain investigational and require independent evidence appropriate to their respective indications.
The development strategy builds partly on earlier GDFATHER Phase 1/2a findings in heavily pretreated patients whose disease had progressed following checkpoint inhibitor treatment. In that programme, CatalYm reported objective response rates of approximately 18% in non-squamous lung cancer and urothelial carcinoma cohorts, with evidence of durable responses among selected patients. Such findings support investigation of immune resistance mechanisms but do not establish efficacy in newly diagnosed disease.
Visugromab is also being studied in cancer-associated cachexia through the VINCIT Phase 2/3 programme. GDF-15 is involved in biological signalling associated with appetite and body-weight regulation, providing a separate therapeutic rationale. The cachexia programme has different clinical objectives from the oncology trials, and outcomes in one development pathway cannot establish benefits in another.
For CatalYm, the expanding research portfolio creates opportunities to test whether GDF-15 neutralisation offers clinically useful effects across different biological contexts. However, the breadth of development also increases the need for sufficient funding, trial execution and careful prioritisation. Success in an exploratory bladder cancer study does not guarantee that the antibody will work in other tumor types.
What are the financial and strategic implications of CatalYm’s latest Phase 2 findings?
CatalYm is a privately held biotechnology company based in Munich, Germany, with operations in San Francisco. Its investor base includes venture capital and healthcare investment firms supporting the development of its GDF-15-targeted technology. Unlike publicly traded biotechnology companies, CatalYm does not have a continuously quoted share price through which investors can assess the immediate market reaction to the ESMO results.
The Nature Medicine publication and updated Phase 2 evidence could strengthen the company’s position when engaging potential pharmaceutical partners, investors and clinical research collaborators. Peer-reviewed evidence is valuable because it permits external examination of the trial design and reported findings, although publication does not establish regulatory readiness. The size and maturity of the underlying clinical dataset remain central to the programme’s valuation.
CatalYm’s commercial opportunity will depend on whether visugromab demonstrates reproducible clinical benefits in larger trials. A medicine that enhances checkpoint inhibitor responses across several tumor types could have broad development potential, but the ultimate addressable population would depend on approved indications, biomarker requirements and competition.
The company’s current disclosure does not establish a regulatory filing date for bladder cancer or a commercial launch timeline. Any revenue potential remains prospective, while continued trials will require capital and operational resources before marketing authorisation can be considered.
The most consequential near-term development question is whether the improved response rates can be reproduced in a larger study designed to establish clinically meaningful outcomes. A stronger evidence package could create opportunities for further partnerships or programme expansion, but those developments should not be assumed from the existing Phase 2 results.
What evidence will determine whether visugromab can change bladder cancer treatment?
The GDFATHER-NEO findings provide early randomised evidence that GDF-15 neutralisation may improve the antitumor activity of nivolumab in patients with muscle-invasive bladder cancer. The observed differences in pathological and radiographic response, together with supportive central review, justify further evaluation of the biological approach. However, the exploratory design and small sample size prevent definitive conclusions about long-term efficacy.
Future studies will need to establish whether higher response rates translate into improved event-free survival, lower recurrence risk and better overall outcomes. If bladder preservation becomes a central development objective, a dedicated strategy for patient selection, response assessment and long-term surveillance will be necessary. Clinical benefit would need to be demonstrated without compromising the possibility of cure.
The programme will also need to clarify whether biomarkers such as proliferating CD8-positive T-cell infiltration can reliably identify patients most likely to benefit. Such evidence could support a more precise treatment strategy, particularly if GDF-15 inhibition proves useful only in selected tumor microenvironments.
The October 2026 results strengthen CatalYm’s scientific rationale for pursuing GDF-15 inhibition alongside immune checkpoint therapy. Their longer-term significance will depend on demonstrating that the improved response rates observed in 31 patients can be reproduced in a larger population and, ultimately, translated into durable cancer control with an acceptable safety profile.
